Aortech International PLC
07 August 2006


                                                                   7 August 2006


                           AorTech International plc

                          ("AorTech" or "the Company")

                     First Human Use of Elast-Eon(TM) Polymer
                                        
London - AorTech International plc (AIM: AOR), the medical device development
and biomaterials intellectual property and licensing company, announces the
first FDA approved human use of its polymer technology Elast-Eon pursuant to
its exclusive license agreement with St. Jude Medical (STJ: NYSE) which was
announced on March 20 2006.

Frank Maguire, AorTech CEO said:

"This event represents another significant step forward in the development of
the company and the validation of the Elast-Eon technology. In addition to the
direct benefit of revenues from Elast-Eon sales, the commencement of the human
use phase will provide valuable credibility for Elast-Eon as we expand its use
into other medical markets".

The global market for cardiac pacing and ICD products is in excess of #5.5
billion and grew approximately 8% in 2005.

In addition, the company expects clinical use of its Elast-Eon material to
occur in orthopaedic and urology markets under separate licenses over the next
year.

                                     -Ends-

Enquiries:

AorTech International plc                                      Tel: 801 581 0854
Frank Maguire, Chief Executive Officer

Hogarth PR                                                    Tel: 020 7357 9477
Melanie Toyne-Sewell / Andrew Jaques/
Sarah Richardson






                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
NRAIIFSRTTIDIIR